- Home
- TCRX vs MASS Comparison
TCRX vs MASS Comparison
Compare TCRX & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- MASS
- Stock Information
- Founded
- TCRX 2018
- MASS 2012
- Country
- TCRX United States
- MASS United States
- Employees
- TCRX N/A
- MASS N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- MASS Medical/Dental Instruments
- Sector
- TCRX Health Care
- MASS Health Care
- Exchange
- TCRX Nasdaq
- MASS Nasdaq
- Market Cap
- TCRX 100.7M
- MASS 84.3M
- IPO Year
- TCRX 2021
- MASS 2020
- Fundamental
- Price
- TCRX $1.44
- MASS $7.54
- Analyst Decision
- TCRX Strong Buy
- MASS Buy
- Analyst Count
- TCRX 6
- MASS 3
- Target Price
- TCRX $9.50
- MASS $5.33
- AVG Volume (30 Days)
- TCRX 470.2K
- MASS 624.5K
- Earning Date
- TCRX 08-11-2025
- MASS 08-05-2025
- Dividend Yield
- TCRX N/A
- MASS N/A
- EPS Growth
- TCRX N/A
- MASS N/A
- EPS
- TCRX N/A
- MASS N/A
- Revenue
- TCRX $4,421,000.00
- MASS $63,986,000.00
- Revenue This Year
- TCRX $159.20
- MASS N/A
- Revenue Next Year
- TCRX N/A
- MASS $22.44
- P/E Ratio
- TCRX N/A
- MASS N/A
- Revenue Growth
- TCRX N/A
- MASS 32.85
- 52 Week Low
- TCRX $1.02
- MASS $1.81
- 52 Week High
- TCRX $7.89
- MASS $8.06
- Technical
- Relative Strength Index (RSI)
- TCRX 44.26
- MASS 65.89
- Support Level
- TCRX $1.44
- MASS $6.86
- Resistance Level
- TCRX $1.61
- MASS $7.62
- Average True Range (ATR)
- TCRX 0.16
- MASS 0.58
- MACD
- TCRX -0.02
- MASS 0.06
- Stochastic Oscillator
- TCRX 10.44
- MASS 78.73
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.